SARS-CoV-2 seroprevalence in Aden, Yemen: a population-based study.
Antibodies
COVID-19 serosurvey
ELISA
Immunity
SARS-CoV-2 sero-epidemiology
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
01
10
2021
revised:
10
11
2021
accepted:
10
12
2021
pubmed:
21
12
2021
medline:
19
1
2022
entrez:
20
12
2021
Statut:
ppublish
Résumé
In Yemen, initial surveillance of coronavirus disease 2019 (COVID-19) focused primarily on patients with symptoms or severe disease. The full spectrum of the disease remains unclear. To the best of the authors' knowledge, this is the first seroprevalence study performed in Yemen. This cross-sectional investigation included 2001 participants from all age groups from four districts in Aden, southern Yemen. A multi-stage sampling method was used. Data were collected using a well-structured questionnaire, and blood samples were taken. Healgen COVID-19 IgG/IgM Rapid Diagnostic Test (RDT) Cassettes were used in all participants. All positive RDTs and 14% of negative RDTs underwent enzyme-linked immunosorbent assay (ELISA) testing (WANTAI SARS-CoV-2 Ab ELISA Kit) for confirmation. In total, 549 of 2001 participants were RDT positive and confirmed by ELISA, giving a prevalence of COVID-19 of 27.4%. The prevalence of immunoglobulin G was 25%. The prevalence of asymptomatic COVID-19 in the entire study group was 7.9%. The highest prevalence was observed in Al-Mansurah district (33.4%). Regarding sociodemographic factors, the prevalence of COVID-19 was significantly higher among females, housewives and subjects with a history of contact with a COVID-19 patient: 32%, 31% and 39%, respectively. This study found high prevalence of COVID-19 in the study population. Household transmission was common.
Sections du résumé
BACKGROUND
BACKGROUND
In Yemen, initial surveillance of coronavirus disease 2019 (COVID-19) focused primarily on patients with symptoms or severe disease. The full spectrum of the disease remains unclear. To the best of the authors' knowledge, this is the first seroprevalence study performed in Yemen.
METHODS
METHODS
This cross-sectional investigation included 2001 participants from all age groups from four districts in Aden, southern Yemen. A multi-stage sampling method was used. Data were collected using a well-structured questionnaire, and blood samples were taken. Healgen COVID-19 IgG/IgM Rapid Diagnostic Test (RDT) Cassettes were used in all participants. All positive RDTs and 14% of negative RDTs underwent enzyme-linked immunosorbent assay (ELISA) testing (WANTAI SARS-CoV-2 Ab ELISA Kit) for confirmation.
RESULTS
RESULTS
In total, 549 of 2001 participants were RDT positive and confirmed by ELISA, giving a prevalence of COVID-19 of 27.4%. The prevalence of immunoglobulin G was 25%. The prevalence of asymptomatic COVID-19 in the entire study group was 7.9%. The highest prevalence was observed in Al-Mansurah district (33.4%). Regarding sociodemographic factors, the prevalence of COVID-19 was significantly higher among females, housewives and subjects with a history of contact with a COVID-19 patient: 32%, 31% and 39%, respectively.
CONCLUSION
CONCLUSIONS
This study found high prevalence of COVID-19 in the study population. Household transmission was common.
Identifiants
pubmed: 34929358
pii: S1201-9712(21)01229-7
doi: 10.1016/j.ijid.2021.12.330
pmc: PMC8677627
pii:
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin M
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
239-244Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement None declared.
Références
Lancet Infect Dis. 2020 Jul;20(7):774-775
pubmed: 32243815
PLoS Med. 2020 Sep 22;17(9):e1003346
pubmed: 32960881
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
JAMA Intern Med. 2021 Apr 1;181(4):450-460
pubmed: 33231628
J Public Health (Oxf). 2021 Apr 12;43(1):3-8
pubmed: 32940328
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):200-206
pubmed: 33412811
JAMA Intern Med. 2020 Sep 1;180(9):1156-1163
pubmed: 32356867
JAMA. 2020 May 12;323(18):1775-1776
pubmed: 32203977
Lancet. 2020 Mar 14;395(10227):841-842
pubmed: 32113508
J Med Virol. 2020 Jun;92(6):577-583
pubmed: 32162702
Lancet. 2020 Oct 24;396(10259):1335-1344
pubmed: 32987007
Rev Panam Salud Publica. 2020 Oct 06;44:e108
pubmed: 33042199
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Lancet. 2020 Aug 1;396(10247):313-319
pubmed: 32534626
J Infect Dis. 2020 Sep 1;222(7):1086-1089
pubmed: 32750135
Lancet Infect Dis. 2020 Oct;20(10):1141-1150
pubmed: 32562601
Glob Health Res Policy. 2020 Jul 1;5:33
pubmed: 32617414
Nature. 1985 Nov 28-Dec 4;318(6044):323-9
pubmed: 3906406
Nat Commun. 2020 Sep 17;11(1):4704
pubmed: 32943637
Clin Microbiol Infect. 2021 Mar;27(3):331-340
pubmed: 33228974
Nat Med. 2020 Apr;26(4):506-510
pubmed: 32284616
Lancet. 2020 Aug 22;396(10250):535-544
pubmed: 32645347